OBJECTIVE: To describe prescribing practices and costs of antihypertensive medications in a large employee health program one to three years after the issuance of the recommendations of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC) for initial treatment of uncomplicated hypertension with beta blockers and diuretics as monotherapy, based on ample evidence that these agents reduce morbidity and mortality. SETTING: Employee health plan for Westinghouse Electric Corp. PATIENTS: 1 ,218 newly diagnosed hypertensives DESIGN: To evaluate initial pharmacotherapy for newly medicated hypertensives and adherence to the JNC-V recommendations, paid medicaVphannacy claims from Westinghouse Electric Corporation's employee health plan for 1994-96 were analyzed. This analysis was modeled after a similar study of John Deere employees in which the majority received monotherapy with calcium channel blockers or ACE inhibitors. RESULTS: Of 16,523 employees with hypertension, 1,218 were newly treated with pharmacotherapy. The initially prescribed agents for these newly medicated hypertensives were': beta blockers 20%, diuretics 19%, calcium channel blockers 23%, ACE inhibitors 23%, and others 15%. Medication with ACE inhibitors and calcium channel blockers was four to five times more costly than treatment with diuretics and beta blockers. CONCLUSION: By 1996, prescribing patterns for newly medicated hypertensive patients had not changed significantly since the JNC-V recommendations. Physician prescribing habits continue to show that the primary drugs recommended for initial treatment of hypertension are used only 39% of the time. Health plans may have the opportunity to influence care in a clinically appropriate manner with medications that have lower costs by focusing on beta blockers and diuretics for first-line treatment of uncomplicated hypertension. KEYWORDS: Hypertension, Antihypertensive medications, JNC-V recommendations J Managed Care Pharm 1999: 505-509
Evaluation of Initial Drug Selection For Newly Medicated Hypertensives at the Westinghouse Electric Corporation recommended mono therapy with either hydrochlorothiazide or beta blockers for initial treatment of uncomplicated hypertension. 6 Those recommendations were reinforced in the JNC-VI guidelines issued in November 1997, with the added provision that low-dose combinations of diuretics with other antihypertensives are also acceptableB Although these recommendations have been challenged by advocates of newer antihypertensive agents such as calcium channel blockers, alpha blockers, ACE inhibitors, and angiotensin receptor blockers, diuretics and beta blockers remain the only classes of drugs that have been widely documented to reduce morbidity and mortality from hypertension-associated cardiovascular disease.6.s.9
Two large metaanalyses have established the efficacy of beta blockers and diuretics and the long-term morbidity and mortality outcomes associated with their use. Collins et al. performed a meta analysis of 37,000 individuals in 14 randomized clinical controlled trials in which the chief agents used were beta blockers and diuretics' Mean diastolic blood pressure (DBP) was reduced by 5 mm Hg to 6 mm Hg and clinical outcomes were significantly improved with a 42% reduction in stroke, a 14% reduction in CHD, and a 21 % reduction in vascular mortality' Psaty 
Regardless of the IN C-V recommendations and cumulative
clinical evidence, use of beta blockers and diuretics has declined dramatically9,1l'ls Calcium channel blockers and ACE inhibitors are commonly prescribed as initial agents, cost up to 30 times more than beta blockers and diuretics, and place a significant cost burden on health care payors and patients. Yet the magnitude of these drugs' effects on morbidity and/or mortality from cardiovascular causes has not been fully documented.6.8, 9 In 1994, the Westinghouse Electric Corporation of Pittsburgh, PA, began analyzing paid claims data from its self-funded corporate health benefit program for its members nationwide to ascertain appropriateness of first-line antihypertensive medications prescribed for patients who were newly receiving pharmacotherapy to manage their hypertension. The researchers also evaluated medication-taking behavior, high-cost hypertensive patients, and use of beta blockers after myocardial infarction. This paper .describes the claims analysis and characterizes first- Patients who were prescribed a drug from a single pharmacologic class but had agents from one or more other classes added to their regimen at least seven days after initial therapy
Dual therapy (2+ Drugs)
Patients who were prescribed a drug from a single pharmacologic class but had agents from one or more other classes added to their regimen within five days after initial therapy Sequential monotherapy Patients who were prescribed two or more drugs from separate pharmacologic classes but never concurrently and diuretics. Average prescription expenditures for ACE inhibitors and calcium channel blockers were four to five times higher than those for diuretics and beta blockers.
DISCUSSION
The findings in this analysis are consistent with national trends of underutilization of beta blockers and diuretics9.II.12.IS Although 64% of employees were treated with mono therapy at Westinghouse, calcium channel blockers and ACE inhibitors represented 42% of all prescriptions for monotherapy (see Table 2 ). Analyzed across all types of therapy, calcium channel blockers and ACE inhibitors accounted for 46% of all initial prescriptions, while beta blockers and diuretics made up only 39%. Use of ACE inhibitors and calcium channel blockers as initial therapy was not associated with ICD-9 codes of ischemic heart disease or congestive heart failure. Hypertension is a chronic condition requiring persistent, long-term treatment that carries a substantial cost for both insurers and patients. The choice of initial pharmacotherapy is important in controlling these costs. In our claims analysis, total expenditures reflect the pharmaceutical budgetary impact on Westinghouse. Expenditures for calcium channel blockers and ACE inhibitors were several times greater than those for beta blockers and diuretics (see Table 2 ). On a global level, 1996 prescription expenditures of health maintenance organi-zations (HMOs) were much higher for the newer classes of antihypertensives, totaling $341.5 million for ACE inhibitors, $471 million for calcium channel blockers, and $157.6 million for beta blockers.26 Per member per year HMO expenditures were $3.05, $6.06, and $9.11 (or beta blockers, ACE inhibitors and calcium channel blockers, respectively.
Underutilization of beta blockers and diuretics may be attributable to widely held perceptions that they have more
Formularies were originally developed to promote appropriate prescribing and to control costs. Yet rebates and incentive programs can influence which drugs attain formulary status and which drugs are prescribed. Several calcium channel blockers and virtually all ACE inhibitors are branded, while the majority of diuretics and beta blockers have generic equivalents with no available rebates or incentives.
In the setting of employer health programs, the Westinghouse data validate and confirm the prescribing trends observed by John Deere researchers (see Table 3 ), and lead to the same con- 
